Conmind Medical, a China-based brain science and medical technology platform, has secured RMB 200 million (USD 29 million) in a Series C funding round led by Zhongshan Venture Capital, with participation from Yuecai Zhongyin Venture Equity, Technology Financial Group, and other undisclosed investors.
The capital infusion will accelerate commercialization of Conmind’s globally innovative “Cardio-Cerebral Integrated Care” device solution, which recently completed all clinical trials, and expand its end-to-end platform spanning prevention, treatment, and functional rehabilitation of brain-related conditions.
Funding Details
| Item | Detail |
|---|---|
| Round | Series C |
| Amount | RMB 200 million (≈ USD 29 million) |
| Lead Investor | Zhongshan Venture Capital |
| Participating Investors | Yuecai Zhongyin Venture Equity, Technology Financial Group, others |
| Use of Proceeds | Clinical commercialization, BCI R&D scale-up, regulatory submissions |
Technology & Product Portfolio
- Core Platforms: Minimally invasive interventional neurotechnology + proprietary brain-computer interface (BCI) infrastructure
- Early Focus: Complete product suite for interventional treatment of cerebrovascular diseases, solving critical bottlenecks in biomaterials, precision microfabrication, and catheter-based delivery systems
- Strategic Expansion: Parallel development of BCI core components—including neural signal acquisition, decoding algorithms, and closed-loop neuromodulation hardware
- Flagship Innovation: “Cardio-Cerebral Integrated Care” — a world-first integrated device system linking cardiovascular and cerebral monitoring/therapy, now post-clinical-trial and poised for regulatory filing
Clinical & Commercial Outlook
- Clinical Status: All pivotal trials for the Cardio-Cerebral Integrated Care platform successfully completed; data shows significant improvement in functional recovery metrics vs. standard care
- Market Opportunity: Addresses China’s growing burden of stroke and neurodegenerative disorders, with an estimated 13 million new cerebrovascular cases annually
- Differentiation: Only Chinese medtech firm combining interventional neuroradiology with scalable BCI architecture, enabling real-time brain-state feedback during therapy
- Regulatory Pathway: Preparing NMPA Class III submissions for lead products in H2 2026
Forward-Looking Statements
This brief contains forward-looking information regarding regulatory timelines, product launches, and market adoption. Actual outcomes may vary due to clinical, regulatory, and competitive risks.-Fineline Info & Tech